礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09637 礼邦医药-B

已收盘 11-12 16:08:04

21.220

+0.220

+1.05%

最高21.600	最低20.460	成交量25.56万
今开20.460	昨收21.000	日振幅5.43%
总市值73.85亿	流通市值50.08亿	总股本3.48亿
成交额542.07万	换手率0.11%	流通股本2.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":21.22,"timestamp":1794470884873,"preClose":21,"halted":0,"volume":255600,"delay":0,"changeRate":0.010476190476190422,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"已收盘","change":0.22,"latestTime":"11-12 16:08:04","open":20.46,"high":21.6,"low":20.46,"amount":5420702,"amplitude":0.054286,"askPrice":21.22,"askSize":2200,"bidPrice":21.1,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":21,"openAndCloseTimeList":[[1794447000000,1794456000000],[1794459600000,1794470400000]],"volumeRatio":0.405234,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09637","defaultTab":"news","newsList":[{"id":"1199674611","title":"礼邦医药-B：11月6日回购200股，涉资约3,604.00港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199674611","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199674611?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:11","pubTimestamp":1793974317,"startTime":"0","endTime":"0","summary":"礼邦医药（江苏）股份有限公司于2026年11月6日公告，通过翌日披露报表确认当日于香港联交所场内回购200股H股。本次回购股份占董事会公告前公司已发行股本约0.0001%，每股价格为18.02港元，涉资约3,604.00港元。根据公司公告，本次回购得到2026年8月14日通过的购回授权支持，授权下可回购总数为23,563,548股，公告显示公司已在境内外证券交易所合计回购151,400股。公司确认本次回购符合香港联合交易所有限公司证券上市规则及相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B：11月6日回购200股，涉资约3,604.00港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681862580","title":"礼邦医药-B(09637.HK)11月6日斥资3604港元回购200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681862580","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681862580?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:01","pubTimestamp":1793973706,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","09637","BK1574","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144546289","title":"礼邦医药-B回购6,600股股份，总额约11.54万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144546289","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144546289?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:06","pubTimestamp":1793887591,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司于2026年11月5日公告，称公司当日在香港联合交易所场内回购6,600股H股股份，占该次回购前已发行股份总数的约0.0028%。最高回购价每股17.64港元，最低回购价每股17.29港元，合计耗资115,351港元。本次回购完成后，公司持有库存股数量增至151,200股，已发行股份减少至235,484,289股，总发行股份数仍为235,635,489股。公司表示，本次回购依据2026年8月14日通过的购回授权进行，授权范围为最多回购23,563,548股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B回购6,600股股份，总额约11.54万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681966079","title":"礼邦医药-B(09637)11月5日斥资约11.54万港元回购6600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681966079","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681966079?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:03","pubTimestamp":1793887391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B(09637)发布公告，于2026年11月5日该公司斥资约11.54万港元回购6600股，回购价格为每股17.29至17.64港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","09939","09637","BK1161","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177433767","title":"礼邦医药-B回购7.41万股股份，总额约124.85万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177433767","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177433767?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:06","pubTimestamp":1793801183,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司于2026年11月4日发布翌日披露报表，公告称公司当日于香港联合交易所场内回购7.41万股H股，占当日已发行H股股份总数的约0.0315%。本次回购价格区间为每股16.38港元至17.40港元，平均回购价约16.85港元，合计耗资约124.85万港元。此项变动后，公司已发行H股股份总数为235,490,889股，库藏股数量增至144,600股。公告同时披露，此次回购完成后，至2026年12月4日期间，公司将暂停发行新股或出售、转让库藏股份，除非事先获得香港联交所批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B回购7.41万股股份，总额约124.85万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680026052","title":"礼邦医药-B(09637.HK)11月4日耗资约124.85万港元回购7.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680026052","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680026052?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:01","pubTimestamp":1793800916,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","BK1574","09939","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170094243","title":"礼邦医药-B10月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1170094243","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170094243?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:51","pubTimestamp":1793782269,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司于2026年11月4日发布2026年10月股份变动月报表，披露了公司当月股本结构和已发行股份变动情况。报告期内，公司总股本未发生任何变动。根据公告，截至2026年10月31日，礼邦医药-B的注册股本由235,635,489股H股和112,730,042股内资股组成，合计348,365,531股。上述H股和内资股数量与上月末一致，未出现新增发行、购回、注销或库藏股变动。礼邦医药-B在公告中确认，其截至10月底仍符合香港联交所关于公众持股量的相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120071766","title":"礼邦医药-B回购12,200股H股，涉资约20.02万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120071766","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120071766?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:06","pubTimestamp":1793714778,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司于2026年11月3日发布公告，披露当日通过香港联合交易所场内回购12,200股H股，约占当时已发行股本的0.0052%。每股回购价格介乎港币16.22元至16.60元，总耗资约港币200,206元。本次回购完成后，公司已发行股本合计235,635,489股，其中流通股为235,564,989股，库藏股为70,500股。公司表示此前已于2026年8月14日获股东大会批准进行股份购回授权，授权总数为23,563,548股。根据上市规则相关规定，下一次新股发行或库藏股再次出售须遵守暂止期至2026年12月3日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B回购12,200股H股，涉资约20.02万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680797284","title":"1亿港元回购计划打响“第一枪”！礼邦医药-B(09637)首笔近百万港元回购落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2680797284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680797284?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:10","pubTimestamp":1793668200,"startTime":"0","endTime":"0","summary":"此次回购是公司此前公布的回购计划的具体落实。2026年10月20日，礼邦医药宣布，将根据股东于临时股东大会授予的一般性授权，在授权有效期及授权范围内，视市场情况于公开市场购回H股，回购总额上限为1亿港元，包括经纪佣金、印花税等相关交易费用。礼邦医药专注于肾脏疾病及相关慢性病领域，产品组合覆盖慢性肾脏病不同阶段及其并发症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IOSX","AAPY","AAPU","AAPW","BK1574","BK1191","AAPE","AAPD","09939","159938","09637","AAPB","AAPX","BK1161","APLY","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162714599","title":"礼邦医药-B回购5.83万股股份，耗资约99.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162714599","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162714599?lang=zh_cn&edition=full","pubTime":"2026-11-02 22:06","pubTimestamp":1793628366,"startTime":"0","endTime":"0","summary":"礼邦医药（江苏）股份有限公司于2026年11月2日发布公告，宣布当日在香港联交所回购股份。根据公告，本次回购涉及5.83万股H股，占回购前公司已发行股本的约0.0247%，每股价格介乎16.57港元至17.19港元，合计动用约99.59万港元。本次股份回购完成后，公司已发行股本由235,635,489股减少至235,577,189股，同时新增58,300股列作库存股。据公告显示，以上信息由礼邦医药（江苏）股份有限公司联席公司秘书陈南佑签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"礼邦医药-B回购5.83万股股份，耗资约99.59万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678146039","title":"港股异动 | 礼邦医药-B(09637)早盘涨超10% 合作伙伴R1已于ASN肾脏周展示AP306全球IIb期多区域临床试验设计壁报","url":"https://stock-news.laohu8.com/highlight/detail?id=2678146039","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678146039?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:32","pubTimestamp":1793068352,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B早盘涨超10%。该项全球IIb期多区域临床试验由礼邦医药与R1共同申办，目前正在美国及中国的多个临床中心开展。公司已于2026年7月21日就该试验完成首例受试者随机化并给药进行公告，目前美国及中国临床中心的受试者招募正在进行中，预计试验将于2027年第二季度完成，顶线数据将在适当时候公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4588","BK1161","MDTX","KCAI","VXUS","IBBQ","BK1191","PSYK","BK1574","BK1515","09939","BMED","09637","159938","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677446643","title":"港股异动 | 礼邦医药-B(09637.HK)高开逾6% 拟在公开市场购回H股 总金额不超过1亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677446643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677446643?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:25","pubTimestamp":1792545914,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","09637","BK1191","BK1574","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676769362","title":"礼邦医药-B(09637)拟回购不超过1亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676769362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676769362?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:08","pubTimestamp":1792498138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 公布，董事会已议决根据于2026年8月14日举行的临时股东会上经公司股东批准并授予公司董事的一般授权，不时于香港联合交易所有限公司公开市场购回公司H股，总金额不超过1亿港元。经考虑H股的交易表现、公司的业务及财务状况、资金需求以及股东的整体利益，董事会认为股份购回属必要及合理。在届时可获得的适用股份购回授权范围内，公司或会根据市况进一步购回H股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09637","BK1191","BK1515","BK1161","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157050182","title":"礼邦医药-B(09637)获授权回购不超过1亿港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157050182","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157050182?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:06","pubTimestamp":1792497973,"startTime":"0","endTime":"0","summary":"10月20日，礼邦医药-B发布自愿公告称，董事会已议决在香港联交所场内回购公司H股，累计支付总额不超过1亿港元。本次回购基于2026年8月14日召开的临时股东会上获通过的一般性股份回购授权。董事会表示，回购目的在于维护公司价值及股东利益。公司提醒股东及潜在投资者，是否回购及具体规模将视乎市况，由董事会及其授权人士决定，不保证任何回购的时间、数量或价格。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676187653","title":"礼邦医药-B早盘一度飙升逾47% AP308获FDA临床许可及国内受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676187653","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676187653?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:22","pubTimestamp":1792462920,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。礼邦医药-B早盘一度飙升逾47%。截至发稿，股价回落现涨11.04%，报19.41港元，成交额8187.61万港元。北大医院近日宣布，其肾脏内科与礼邦医药联合开发的新一代AP308/PKU308用于治疗IgA肾病的新药临床试验申请获美国FDA批准，即将进入首次人体临床研究阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-20/doc-inivvsvt5849002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","LABU","159938","BK4588","BK1574","09637","09939","BK4585","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665806","title":"港股异动 | 礼邦医药-B(09637.HK)飙升逾46% AP308获FDA临床许可及国内受理 全球化布局价值有望兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665806?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:03","pubTimestamp":1792461837,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1574","09939","BK1515","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675563356","title":"港股异动 | 礼邦医药-B(09637.HK)盘中一度涨近4% 振幅达13.53% 港股创新药板块集体走强 AP308治疗IgA肾病新药临床试验获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675563356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675563356?lang=zh_cn&edition=full","pubTime":"2026-10-16 12:47","pubTimestamp":1792126069,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","09939","BK1574","06978","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062289","title":"港股异动 | 礼邦医药-B(09637)早盘涨近7% 机构指AP308有望解锁更加广阔的IgA肾病市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062289","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673062289?lang=zh_cn&edition=full","pubTime":"2026-10-07 11:00","pubTimestamp":1791342052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B早盘涨近7%。截至发稿，涨2.78%，报27.4港元，成交额641.32万港元。消息面上，礼邦医药近期发布公告，其工程化重组IgA蛋白酶AP308用于治疗IgA肾病的新药临床试验申请获美国FDA批准，公司计划近期启动首次人体临床试验。按公司公告表述，AP308为已知首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。尤其AP308若能验证能够实现IgA肾病的功能性治愈，则有望解锁更加广阔的IgA肾病市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1191","09939","BK4588","KCAI","BK4585","VXUS","159938","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673543290","title":"五连涨，阶段低点以来跑赢恒指18.5个百分点：肾脏病的风口来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2673543290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673543290?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:49","pubTimestamp":1791294554,"startTime":"0","endTime":"0","summary":"截至10月6日收盘，礼邦医药报26.66港元，录得五连涨，较9月28日收盘累计上涨13.7%。按9月14日23港元的阶段收盘低点起算，累计反弹15.9%；同期恒生指数下跌2.6%，跑赢约18.5个百分点。共同病理机制、多适应症开发与全球权益，让AP303成为礼邦拓展肾脏病治疗版图的重要支点。全球IIb期多区域临床试验已完成首例受试者随机化并给药。五连涨背后值得关注的，是肾脏病行业的新机制、商业化增量与公司自身管线进展开始形成呼应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165566387","title":"礼邦医药-B更新2026年9月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1165566387","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165566387?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:49","pubTimestamp":1791276570,"startTime":"0","endTime":"0","summary":"礼邦医药(江蘇)股份有限公司于2026年10月6日发布了截至2026年9月30日止当月的股份变动月报表。公告显示，公司注册股本合计为人民币348,365,531元，其中包括已在香港联交所上市的H股普通股235,635,489股，每股面值人民币1元，内资股普通股112,730,042股，每股面值人民币1元。上述各类注册股本在2026年9月期间均无新增或减少，维持不变。礼邦医药-B表示，截至本月末，其上市H股的公众持股比例符合香港联交所相关上市规则及最低公众持股量的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alebund.com","stockEarnings":[{"period":"1week","weight":0.2069},{"period":"1month","weight":-0.1532},{"period":"3month","weight":-0.3834},{"period":"6month","weight":-0.0708},{"period":"ytd","weight":-0.0708}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0634},{"period":"1year","weight":-0.0892},{"period":"ytd","weight":-0.0513}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"礼邦医药（江苏）股份有限公司是一家主要从事生物制药的中国公司。该公司的临床及临床前产品组合由一款核心产品AP301及其他候选产品组成，包括：一款临床后期候选产品（AP306）、一款临床前期候选药物（AP303），以及四款临床前候选药物（AP308、AP304、AP305与AP307）。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"礼邦医药-B","nameEN":"ALEBUND-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼邦医药-B,09637,礼邦医药-B股票,礼邦医药-B股票老虎,礼邦医药-B股票老虎国际,礼邦医药-B行情,礼邦医药-B股票行情,礼邦医药-B股价,礼邦医药-B股市,礼邦医药-B股票价格,礼邦医药-B股票交易,礼邦医药-B股票购买,礼邦医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}